Kenvue Inc. to Issue Quarterly Dividend of $0.20 (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Shareholders of record on Wednesday, May 8th will be paid a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 dividend on an annualized basis and a yield of 4.21%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue has a dividend payout ratio of 64.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.02 on Friday. Kenvue has a 12 month low of $17.82 and a 12 month high of $27.80. The company’s fifty day simple moving average is $19.84 and its 200-day simple moving average is $20.14. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue’s quarterly revenue was down 2.7% on a year-over-year basis. On average, research analysts predict that Kenvue will post 1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KVUE has been the topic of a number of analyst reports. Royal Bank of Canada reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective on the stock. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.